<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2702">
  <stage>Registered</stage>
  <submitdate>11/03/2010</submitdate>
  <approvaldate>11/03/2010</approvaldate>
  <nctid>NCT01087151</nctid>
  <trial_identification>
    <studytitle>A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)</studytitle>
    <scientifictitle>A Phase II, Multicenter, Randomized, Controlled, Open-label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-intensive Rituximab, or Dose-intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2009-012152-24</secondaryid>
    <secondaryid>ABT4710n</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Lymphocytic Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ABT-263
Treatment: drugs - rituximab

Active Comparator: A - 

Experimental: B - 

Experimental: C - 


Treatment: drugs: ABT-263
Oral repeating dose

Treatment: drugs: rituximab
Intravenous repeating dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>From randomization to the first occurrence of progression, relapse, or death on study (approximately 40 months from First Patient In [FPI])</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR)</outcome>
      <timepoint>Approximately 40 months from FPI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>Approximately 40 months from FPI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete response (CR) rate</outcome>
      <timepoint>Approximately 40 months from FPI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival as assessed by a blinded, independent review</outcome>
      <timepoint>From randomization to the first occurrence of progression, relapse, or death on study (approximately 40 months from FPI)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ORR as assessed by a blinded, independent review</outcome>
      <timepoint>Approximately 40 months from FPI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response as assessed by a blinded, independent review</outcome>
      <timepoint>Approximately 40 months from FPI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CR rate as assessed by a blinded, independent review</outcome>
      <timepoint>Approximately 40 months from FPI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival (OS)</outcome>
      <timepoint>From randomization until death due to any cause (approximately 4 years after Last Patient In)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Previously untreated, CD20-positive B-cell CLL

          -  ECOG performance status of 0 or 1

          -  Life expectancy &gt; 6 months

          -  Willingness and capability to be accessible for follow-up until study termination or
             death

          -  For patients of reproductive potential (both males and females), use of a reliable
             means of contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prolymphocytic leukemia

          -  Richter's transformation to an aggressive B-cell malignancy (e.g., DLBCL)

          -  Prior radiotherapy to a lesion(s) that will be used to assess response unless that
             lesion(s) shows clear evidence of progression at baseline

          -  Patients with a history of other malignancies within 2 years prior to study entry
             except for adequately treated carcinoma in situ of the cervix, basal or squamous cell
             skin carcinoma, low-grade, localized prostate cancer treated surgically with curative
             intent or one that carries a good prognosis, in situ ductal carcinoma of the breast
             treated with lumpectomy alone with curative intent

          -  Prior treatment with rituximab, ABT-263 or other pro-apoptotic agents

          -  Current or recent (within the 28 days prior to initiation of study treatment)
             participation in another experimental drug study

          -  Major surgical procedure (excluding lymph node biopsy) or significant traumatic injury
             within 28 days prior to treatment onset or anticipation of the need for major surgery
             during the course of the study

          -  Active infection requiring parenteral antibiotics or antiviral or antifungal agents at
             the onset of study treatment

          -  Receipt of primary or booster vaccination with live-virus vaccines for up to 6 months
             prior to initiation of study treatment

          -  Patients receiving therapeutic anticoagulation with heparin or warfarin or patients
             receiving any drugs or herbal supplements that are known to inhibit platelet function
             (including low-dose aspirin) within 7 days of the first dose of ABT-263. Note:
             Patients receiving low-dose anticoagulation for the purpose of maintaining central
             venous catheter patency are eligible.

          -  Patients who have an inherited or acquired bleeding diathesis, including (but not
             limited to) hemophilia or immune or thrombotic thrombocytopenic purpura, or who have
             had an underlying condition that predisposes to abnormal bleeding (e.g., peptic ulcer
             disease) within 1 year prior to the first dose of ABT-263

          -  Patients with a history of refractoriness to platelet transfusions

          -  Clinically significant cardiovascular disease

          -  Known human immunodeficiency virus (HIV) infection, seropositivity for hepatitis B
             surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or RNA

          -  Pregnancy or breastfeeding

          -  Concurrent (or within 7 days prior to the first dose of study treatment) systemic
             corticosteroid therapy except some low-dose corticosteroid therapies

          -  History of other disease, metabolic dysfunction, physical or laboratory finding(s)
             giving reasonable suspicion of a disease or condition that contraindicates use of an
             investigational drug, might affect interpretation of the results of the study or
             render the patient at high risk from treatment complications

          -  History of anaphylaxis, allergic reaction, or hypersensitivity to sulfites (sodium
             metabisulphite is included in study drug formulation)

          -  Any contraindication to alcohol ingestion (study drug formulation includes
             approximately 15% ethanol)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>118</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital> - Randwick</hospital>
    <hospital> - Greenslopes</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Kurralta Park</hospital>
    <hospital> - Coburg, VIC</hospital>
    <hospital> - Fitzroy</hospital>
    <hospital> - Frankston</hospital>
    <hospital> - Parkville</hospital>
    <hospital> - Fremantle</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3058 - Coburg, VIC</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3199 - Frankston</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6160 - Fremantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>ES</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>MG</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RJ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pierre Benite</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Afula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petah Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Liguria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chorzow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Petrozavodsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ryazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Cherkassy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Donetsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Ivano-Frankivsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Khmelnitskyy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kyiv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Lviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Poltava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Zhytomir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>AbbVie (prior sponsor, Abbott)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase II, randomized, open-label, international, multicenter trial is designed to
      evaluate the safety and efficacy of rituximab monotherapy when given according to a dose
      intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when
      combined with dose-intense rituximab in previously untreated patients with B-cell CLL.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01087151</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>William Ho, M.D., Ph.D.</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>